Review



soluble gitrl  (Enzo Biochem)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Enzo Biochem soluble gitrl
    Soluble Gitrl, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/soluble+gitrl/pm22911397-77-3-5?v=Enzo+Biochem
    Average 90 stars, based on 1 article reviews
    soluble gitrl - by Bioz Stars, 2026-06
    90/100 stars

    Images



    Similar Products

    low endotoxin soluble gitrl  (R&D Systems)
    92
    R&D Systems low endotoxin soluble gitrl
    Figure 2. GITR engagement partially abrogates suppression mediated by tumor-infiltrating Treg. CD4CCD25¡ effector T cells were isolated from periph- eral blood and labeled with CFSE, and co-cultured during 5 d with autologous mDC activated with CMV antigens. Autologous tumor Treg from HCC- patients (closed symbols) or LM-CRC patients (open symbols) were added in the absence or presence of different concentrations of <t>soluble</t> <t>GITRL</t> (sGITRL). T cell proliferation (A) and cytokine (IFNg and TNFa) production by proliferating cells (B) were measured by flow cytometry after re-stimulation with CMV-activated Mo-DC. Values are also depicted as means §SEM, *p < 0.05, ** p < 0.01, *** p < 0.001. Differences were analyzed by paired t-test.
    Low Endotoxin Soluble Gitrl, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/soluble+gitrl/10__1080_slash_2162402x__2015__1051297-138-5-9?v=R%26D+Systems
    Average 92 stars, based on 1 article reviews
    low endotoxin soluble gitrl - by Bioz Stars, 2026-06
    92/100 stars
    		  Buy from Supplier
    soluble gitrl  (Enzo Biochem)
    90
    Enzo Biochem soluble gitrl
    Figure 2. GITR engagement partially abrogates suppression mediated by tumor-infiltrating Treg. CD4CCD25¡ effector T cells were isolated from periph- eral blood and labeled with CFSE, and co-cultured during 5 d with autologous mDC activated with CMV antigens. Autologous tumor Treg from HCC- patients (closed symbols) or LM-CRC patients (open symbols) were added in the absence or presence of different concentrations of <t>soluble</t> <t>GITRL</t> (sGITRL). T cell proliferation (A) and cytokine (IFNg and TNFa) production by proliferating cells (B) were measured by flow cytometry after re-stimulation with CMV-activated Mo-DC. Values are also depicted as means §SEM, *p < 0.05, ** p < 0.01, *** p < 0.001. Differences were analyzed by paired t-test.
    Soluble Gitrl, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/soluble+gitrl/pm22911397-77-3-5?v=Enzo+Biochem
    Average 90 stars, based on 1 article reviews
    soluble gitrl - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 2. GITR engagement partially abrogates suppression mediated by tumor-infiltrating Treg. CD4CCD25¡ effector T cells were isolated from periph- eral blood and labeled with CFSE, and co-cultured during 5 d with autologous mDC activated with CMV antigens. Autologous tumor Treg from HCC- patients (closed symbols) or LM-CRC patients (open symbols) were added in the absence or presence of different concentrations of soluble GITRL (sGITRL). T cell proliferation (A) and cytokine (IFNg and TNFa) production by proliferating cells (B) were measured by flow cytometry after re-stimulation with CMV-activated Mo-DC. Values are also depicted as means §SEM, *p < 0.05, ** p < 0.01, *** p < 0.001. Differences were analyzed by paired t-test.

    Journal: OncoImmunology

    Article Title: GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cellsex vivo

    doi: 10.1080/2162402x.2015.1051297

    Figure Lengend Snippet: Figure 2. GITR engagement partially abrogates suppression mediated by tumor-infiltrating Treg. CD4CCD25¡ effector T cells were isolated from periph- eral blood and labeled with CFSE, and co-cultured during 5 d with autologous mDC activated with CMV antigens. Autologous tumor Treg from HCC- patients (closed symbols) or LM-CRC patients (open symbols) were added in the absence or presence of different concentrations of soluble GITRL (sGITRL). T cell proliferation (A) and cytokine (IFNg and TNFa) production by proliferating cells (B) were measured by flow cytometry after re-stimulation with CMV-activated Mo-DC. Values are also depicted as means §SEM, *p < 0.05, ** p < 0.01, *** p < 0.001. Differences were analyzed by paired t-test.

    Article Snippet: In some experiments azide-free and low endotoxin soluble GITRL (R and D systems, Cat. 6987-GL/CF), anti-CTLA-4 neutralizing (BNI3, Beckman Coulter, Cat. IM2070) or isotype control (IgG2a, Biolegend) antibodies were added to the co-cultures.

    Techniques: Isolation, Labeling, Cell Culture, Cytometry

    Figure 5. GITRL and CTLA-4 blockage additively abolish (T)cell suppressive capacity of tumor-infiltrating Treg. Blood-derived CFSE-labeled CD4CCD25¡ T cells from HCC-patients or LM-CRC patients were co-cultured with autologous CMV-DC for 5 d Autologous tumor derived Treg were added in a ratio 1:5. Cells were treated with 10 mg/mL of anti-CTLA-4 mAb or GITRL or a combination of both. Cell proliferation and cytokine production were analyzed by flow cytometry after re-stimulation with CMV-activated Mo-DC. (A) Depicts a representative experiment showing T cell proliferation, IFNg and TNFa pro- duction after co-culture and re-stimulation. (B) Collective data of 5 patients tested (3 LM-CRC and 2 HCC) showing the relative T cell proliferation or cyto- kine production (IFNg and TNFa) by proliferating cells. Values are means § SEM, * p < 0.05, ** p < 0.01, *** p < 0.001. Comparison between groups was made by paired t-test.

    Journal: OncoImmunology

    Article Title: GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cellsex vivo

    doi: 10.1080/2162402x.2015.1051297

    Figure Lengend Snippet: Figure 5. GITRL and CTLA-4 blockage additively abolish (T)cell suppressive capacity of tumor-infiltrating Treg. Blood-derived CFSE-labeled CD4CCD25¡ T cells from HCC-patients or LM-CRC patients were co-cultured with autologous CMV-DC for 5 d Autologous tumor derived Treg were added in a ratio 1:5. Cells were treated with 10 mg/mL of anti-CTLA-4 mAb or GITRL or a combination of both. Cell proliferation and cytokine production were analyzed by flow cytometry after re-stimulation with CMV-activated Mo-DC. (A) Depicts a representative experiment showing T cell proliferation, IFNg and TNFa pro- duction after co-culture and re-stimulation. (B) Collective data of 5 patients tested (3 LM-CRC and 2 HCC) showing the relative T cell proliferation or cyto- kine production (IFNg and TNFa) by proliferating cells. Values are means § SEM, * p < 0.05, ** p < 0.01, *** p < 0.001. Comparison between groups was made by paired t-test.

    Article Snippet: In some experiments azide-free and low endotoxin soluble GITRL (R and D systems, Cat. 6987-GL/CF), anti-CTLA-4 neutralizing (BNI3, Beckman Coulter, Cat. IM2070) or isotype control (IgG2a, Biolegend) antibodies were added to the co-cultures.

    Techniques: Derivative Assay, Labeling, Cell Culture, Cytometry, Co-Culture Assay, Comparison

    Figure 6. Treatment with GITRL and anti-CTLA-4 antibody can recover ex vivo antitumor T-cell immunity. Blood mDC activated with autologous TL were used to stimulate CFSE-labeled autologous peripheral CD4CCD25¡ T cells for one week. In some cultures autologous Ti-Treg were added and cells were treated with 10 mg/mL of an isotype control antibody or with a mixture of 10 mg/mL of GITRL and 10 mg/mL of anti-CTLA-4 antibody. T cell proliferation and cytokine production were analyzed by flow cytometry after re-stimulation with PMA and ionomycin. Proliferation and cytokine production are reported as fold increase of specific T cell proliferation or cytokine production, calculated by dividing the percentage of proliferation or cytokine produc- tion (TNFa or IFNg) in the mDC C TL condition by that in the control condition without TL (medium DC). (A) A representative analysis from one patient and (B) Collective data from 3 different patients tested. HCC (closed symbols) or LM-CRC (open symbols).

    Journal: OncoImmunology

    Article Title: GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cellsex vivo

    doi: 10.1080/2162402x.2015.1051297

    Figure Lengend Snippet: Figure 6. Treatment with GITRL and anti-CTLA-4 antibody can recover ex vivo antitumor T-cell immunity. Blood mDC activated with autologous TL were used to stimulate CFSE-labeled autologous peripheral CD4CCD25¡ T cells for one week. In some cultures autologous Ti-Treg were added and cells were treated with 10 mg/mL of an isotype control antibody or with a mixture of 10 mg/mL of GITRL and 10 mg/mL of anti-CTLA-4 antibody. T cell proliferation and cytokine production were analyzed by flow cytometry after re-stimulation with PMA and ionomycin. Proliferation and cytokine production are reported as fold increase of specific T cell proliferation or cytokine production, calculated by dividing the percentage of proliferation or cytokine produc- tion (TNFa or IFNg) in the mDC C TL condition by that in the control condition without TL (medium DC). (A) A representative analysis from one patient and (B) Collective data from 3 different patients tested. HCC (closed symbols) or LM-CRC (open symbols).

    Article Snippet: In some experiments azide-free and low endotoxin soluble GITRL (R and D systems, Cat. 6987-GL/CF), anti-CTLA-4 neutralizing (BNI3, Beckman Coulter, Cat. IM2070) or isotype control (IgG2a, Biolegend) antibodies were added to the co-cultures.

    Techniques: Ex Vivo, Labeling, Control, Cytometry